期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤生物治疗的新热点——细胞、分子靶向性药物的发展 被引量：11

The highlight of current cancer biotherapy——development of cellular,molecular targeted new agents
下载PDF
导出
摘要 随着分子生物技术的高速发展和对发病机制从细胞、分子水平的进一步认识 ,肿瘤生物治疗已进入了一个全新的时代。本文重点介绍了肿瘤治疗领域中近年来发展的信号转导抑制剂———阻断人类表皮生长因子受体 2 (HER 2 )的Herceptin ,阻断HER 1的ZD1839,OSI 774和C2 2 5。同时也介绍了分子靶向性药物STI5 Following the rapid development of the technology of molecular biology and further understanding of the mechanism of cancer etiology from cellular and molecular levels, biotherapy of cancer has entered a new era. This article focused on the signal transduction inhibitor developed during the recent years in the field of cancer therapy. The new agent includes Herceptin for HER 2 blocking, ZD1839,OSI 774 and C225 for HER 1 blocking.Simultaneously, a molecularly targeted new agent STI571 was introduced for it's breakthrough in the treatment of leukemia and gastrointestinal stromal tumers (GISTs).
作者 储大同
机构地区 中国医学科学院中国协和医科大学肿瘤医院
出处 《中国新药杂志》 CAS CSCD 北大核心 2002年第4期285-288,共4页 Chinese Journal of New Drugs
关键词 生物治疗 信号转导抑制剂 HER-2 HER-1 ZD1839 OSI-774 C225 ST1571 biotherapy signal transduction inhibitor HER 2 HER 1 ZD1839 OSI 774 C225 STI571
分类号 R979.1 [医药卫生—药品]
  • 相关文献

参考文献13

  • 1[1]Seidman AD,Fornier M,Esteva F,et al.Final report:weekly Herceptin and Taxol for metastatic breast cancer:analysis of efficacy by HER-2 immunophenotype [immunohistochemistry (IHC)] and gene amplification [fluorescent in-situ hybridization (FISH)][J].Proc Am Soc Clin Oncol,2000,19∶319.
  • 2[2]Nicholson BP,Thor AD,Goldstein LJ,et al.Weekly docetaxel and rhumabher combination therapy as first or second line treatment for metastatic breast cancer[J].Proc Am Soc Clin Oncol,2000,19∶549.
  • 3[3]Burstein HJ,Kuter I,Richardson PG,et al.Herceptin and Vinorelbine for HER-2 positive metastatic breast cancer:a phase II study[J].Proc Am Soc Clin Oncol,2000,19∶392.
  • 4[4]Sliwkowski MX,Lofgren JA,Lewis GD,et al.Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)[J].Semin Oncol,1999,26(Suppl 12)∶S60-S70.
  • 5[5]Salomon DS,Brandt R,Ciardiello F,et al.Epidermal growth factor-related peptides and their receptors in human malignancies[J].Crit Rev Oncol Hematol,1995,19∶183-232.
  • 6[6]Wu X,Fan Z,Masui H,et al.Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin[J].J Clin Invest,1995,95∶1897-1905.
  • 7[7]Moyer JD,Barbacci EG,Iwata KK,et al.Induction of apoptosis and cell cycle arrest by CP-358,774,an inhibitor of epidermal growth factor receptor tyrosine kinase[J].Cancer Res,1997,57∶4838-4848.
  • 8[8]Kris MG,Herbst R,Rischin D,et al.Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (Iressa),a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)[J].Lung Cancer,2000,29(Suppl 1)∶72(abstract).
  • 9[9]Senzer NN,Soulieres D,Siu L,et al.Phase 2 evaluation of OSI-774,a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck[J].Proc Am Soc Clin Oncol,2001,20∶2a(abstract 6).
  • 10[10]Saltz L,Rubin M,Hochster H,et al.Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor(EGFR)[J].Proc Am Soc Clin Oncol,2001,20∶3a(abstract 7).

同被引文献68

引证文献11

二级引证文献30

中国新药杂志
2002年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部